To assess the postoperative outcomes after implementation of the protocol in patients undergoing surgery for gynaecological malignancies in the COVID-19 pandemic
Not Applicable
- Conditions
- Health Condition 1: N998- Other intraoperative and postprocedural complications and disorders of genitourinary system
- Registration Number
- CTRI/2020/06/025634
- Lead Sponsor
- Dr Kanika Batra Modi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients diagnosed with an ovarian/fallopian tube/peritoneal cancer of any histology
(collectively referred to as ovarian cancer), endometrial cancer surgery, cervical
vulvar or vaginal cancer surgery in all stage, as indicated as indicated for surgery
were included in the trial. The pre-assessment triage including respiratory symptoms,
temperature, history of exposure or travel. Patients selected after this would be
â??screenedâ?? with the RT-PCR test 48â?¯hours before the surgery and then isolated in
their rooms with no visitors allowed.
Exclusion Criteria
Exclusion criteria were:
minimally invasive surgery;
emergency surgery due to any associated cause
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint will be assessment of Length of Hospital Stay (LOS) with the <br/ ><br>implementation of an enhanced recovery after surgery pathway. LOS was defined as <br/ ><br>the number of days from the day of surgery to discharge.Timepoint: 8 Months
- Secondary Outcome Measures
Name Time Method ERAS protocol compliance, Incidence of pre-defined post-operative complications within 30 days after <br/ ><br>surgery, <br/ ><br>Readmission rate <br/ ><br>Time to commencement of adjuvant therapyTimepoint: 8Months